Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 29, 2026

Who in Big Tech Is Ready for Agentic AI?

View original at nasdaq.com
Who in Big Tech Is Ready for Agentic AI? In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Amazon goes after Perplexity's agents.Meta's scattered AI strategy.Oracle's earnings…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moltbook is essentially allowing people and bots to communicate with AI agents in natural language through chat apps

    60% confidence
  • This is more of an admission that the AI strategy is pivoting toward autonomous agents

    60% confidence
  • Oracle is betting they can convert the significant backlog into high margin profits before interest on debt catches up

    60% confidence
  • Meta's next act isn't just smarter chatbots, it's a whole infrastructure for AI agents to interact and transact

    60% confidence
  • The 10 best stocks for investors to buy now don't include Meta Platforms

    60% confidence
  • Meta doesn't know how to get customers to pay for what they're building outside of in-house improvements

    60% confidence
  • When a shift happens, the incumbent usually isn't the beneficiary

    60% confidence
  • The status quo benefits Amazon and it makes sense to preserve it as long as possible

    60% confidence
  • Until AI models are big enough to force the issue, retailers like Amazon have no incentive to give in to Perplexity

    60% confidence
  • If third party AI becomes the primary shopping interface, Amazon's advertising mode could start to dry up

    60% confidence
  • If Oracle can go from $60 billion revenue now to $90 billion in 2027, that's really good

    60% confidence
  • A lot of Oracle's RPO customers may not know if they need all the capacity they've secured

    60% confidence
  • The facts on the ground for Oracle right now are really good and the stock is reflecting that

    60% confidence
  • Amazon's entire flywheel is built on owning the entire commerce journey from first search to package delivery

    60% confidence
  • Oracle's debt of $135 billion is about two times sales and five times EBITDA, which is not unreasonable

    60% confidence
  • Instant and complete comparison shopping could be the killer app for consumers

    60% confidence
  • Oracle is seeing its highest growth in 15 years but it's coming at a staggering cost

    60% confidence
  • Oracle is essentially an AI construction company right now racing to plug in chips faster than the competition

    60% confidence
  • AI agents are tireless shoppers that won't be distracted by deals or browse sponsored results that fuel Amazon's advertising machine

    60% confidence
  • Alphabet has spent about $40 billion on AI related acquisitions

    60% confidence
  • Meta's desperate attempts to get users to use their AI are pretty pathetic right now

    60% confidence
  • If you invested $1,000 in Netflix on December 17, 2004, you'd have $503,861 as of March 28, 2026

    60% confidence
  • Meta has all the cash in the world and is using it to assemble the brightest minds they can

    60% confidence
  • If you invested $1,000 in Nvidia on April 15, 2005, you'd have $1,026,987 as of March 28, 2026

    60% confidence
  • Meta is struggling to develop what they need in house and have found that acquiring outside talent is the best move

    60% confidence

Data points we hold from this source

Stock Advisor · sp500 comparison return179 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Who in Big Tech Is Ready for Agentic AI? — Source | Via News | Via News